\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ was\\ alert\\ and\\ oriented\\.\\ \\ physical\\ exam\\ was\\ significant\\ for\\ 4\\/5\\ strength\\ in\\ right\\ ue\\ and\\ 2\\/5\\ strength\\ in\\ right\\ le\\.\\ \\ no\\ other\\ neurologic\\ deficits\\ were\\ noted\\.\\ \\ hiv\\ test\\ was\\ negative\\.\\ tee\\ demonstrated\\ no\\ vegetations\\.\\ \\ coagulation\\ panel\\ was\\ within\\ normal\\ limits\\.\\ \\ extensive\\ laboratory\\ work\\ up\\ failed\\ to\\ identify\\ any\\ abnormalities\\.\ \(0\)\
\-\ patient\\ was\\ treated\\ with\\ whole\\ brain\\ xrt\\,\\ but\\ could\\ not\\ tolerate\\ the\\ side\\ effects\\.\\ \\ he\\ was\\ discharged\\ to\\ home\\ for\\ palliative\\ care\\.\ \(0\)\
\-\ patient\\ has\\ multiple\\ ring\\-enhancing\\ lesions\\ with\\ increased\\ t2\\ signal\\ within\\ the\\ deep\\ cerebral\\ white\\ matter\\ involving\\ both\\ hemispheres\\.\\ \\ three\\ of\\ the\\ lesions\\ are\\ centered\\ on\\ the\\ periventricular\\ area\\.\\ \\ a\\ fourth\\ lesion\\ is\\ present\\ on\\ the\\ superior\\ portion\\ of\\ the\\ corpus\\ collosum\\ and\\ a\\ fifth\\ cystic\\ lesion\\ in\\ the\\ posterior\\ parieto\\-occiptial\\ area\\.\\ \\ no\\ deviation\\ of\\ the\\ midline\\ is\\ appreciated\\.\ \(0\)\
\-\ brain\\ biopsy\\ confirmed\\ patient\\ has\\ glioblastoma\\ multiforme\\.\ \(0\)\
\-\ lymphoma\\,\\ glioblastoma\\ multiforme\\,\\ tumefactive\\ multiple\\ sclerosis\\,\\ toxoplasmosis\\,\\ neurocystercercosis\\,\\ cryptococcus\ \(0\)\
\-\ patient\\ presented\\ with\\ right\\-sided\\ weakness\\ and\\ tonic\\-clonic\\ activity\\ in\\ his\\ right\\ upper\\ and\\ lower\\ extremity\\.\ \(0\)\
\-\ glioblastome\\ multiforme\\ \\(gbm\\)\\ is\\ the\\ most\\ common\\ type\\ of\\ primary\\ brain\\ tumor\\ in\\ adult\\ patients\\.\\ \\ it\\ has\\ an\\ equal\\ distribution\\ among\\ men\\ and\\ women\\ with\\ a\\ peak\\ incidence\\ in\\ the\\ fifth\\ decade\\ of\\ life\\.\\ \\ it\\ is\\ the\\ most\\ aggressive\\ type\\ of\\ astrocytoma\\ and\\ has\\ a\\ poor\\ prognosis\\.\\ \\ the\\ average\\ survival\\ after\\ diagnosis\\ is\\ eight\\ months\\.\ \(0\)\
\-\ some\\ patients\\ \\(like\\ this\\ one\\)\\ have\\ multicentric\\ gbm\\ which\\ is\\ an\\ uncommon\\ and\\ often\\ more\\ aggressive\\ form\\ of\\ this\\ disease\\,\\ occurring\\ in\\ less\\ than\\ 1\\ \\-\\ 15\\%\\ of\\ patients\\ with\\ gbm\\.\\ \\ it\\ is\\ characterized\\ in\\ this\\ patient\\ by\\ its\\ presence\\ in\\ both\\ cerebral\\ hemispheres\\.\ \(0\)\
\-\ the\\ two\\ most\\ common\\ presenting\\ symptoms\\ are\\ headache\\ and\\ seizure\\.\\ \\ hemiparesis\\ was\\ the\\ most\\ common\\ neurologic\\ deficit\\ at\\ presentation\\ occurring\\ in\\ up\\ to\\ 83\\%\\ of\\ patients\\.\\ \\ this\\ patient\\ denied\\ headaches\\,\\ but\\ did\\ have\\ seizures\\ and\\ hemiparesis\\.\\ \\ the\\ imaging\\ finding\\ of\\ ring\\-enhancing\\ lesions\\ is\\ not\\ specific\\ enough\\ to\\ be\\ diagnostic\\.\\ \\ ultimately\\,\\ a\\ biopsy\\ of\\ the\\ lesions\\ was\\ required\\ for\\ definitive\\ diagnosis\\.ct\\ or\\ mri\\ can\\ be\\ used\\ to\\ image\\ patients\\ with\\ suspected\\ brain\\ lesions\\.\\ \\ however\\,\\ mri\\ is\\ more\\ sensitive\\ and\\ ct\\ can\\ miss\\ lesions\\ in\\ the\\ posterior\\ fossa\\.\\ \\ in\\ a\\ small\\ study\\ looking\\ at\\ imaging\\ in\\ patients\\ with\\ multifocal\\ glioblastoma\\ multiforme\\,\\ it\\ was\\ found\\ that\\ the\\ lesions\\ were\\ always\\ hypointense\\ or\\ isodense\\ on\\ ct\\ and\\ hyperintense\\ on\\ t\\-2\\ weighted\\ mri\\.\\ \\ ring\\-like\\ enhancement\\ was\\ also\\ a\\ common\\ finding\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ multiforme\\:\\ 0\\.0460823278167651\ \(0\)\
\-\ lesions\\:\\ 0\\.037152954859414465\ \(0\)\
\-\ gbm\\:\\ 0\\.035180869895171246\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.03274694589183193\ \(0\)\
\-\ patients\\:\\ 0\\.030787581429689452\ \(0\)\
\-\ ring\\-enhancing\\:\\ 0\\.02937638874328769\ \(0\)\
\-\ hemiparesis\\:\\ 0\\.024682184976798225\ \(0\)\
\-\ brain\\:\\ 0\\.023864051260350457\ \(0\)\
\-\ was\\:\\ 0\\.022929872905189948\ \(0\)\
\-\ occurring\\:\\ 0\\.02214601928599512\ \(0\)\
\-\ fifth\\:\\ 0\\.021755842407987964\ \(0\)\
\-\ hemispheres\\:\\ 0\\.021126861006613377\ \(0\)\
\-\ common\\:\\ 0\\.02075422006456053\ \(0\)\
\-\ parieto\\-occiptial\\:\\ 0\\.020453639034725052\ \(0\)\
\-\ neurocystercercosis\\:\\ 0\\.020453639034725052\ \(0\)\
\-\ glioblastome\\:\\ 0\\.020453639034725052\ \(0\)\
\-\ diagnosis\\.ct\\:\\ 0\\.020453639034725052\ \(0\)\
\-\ aggressive\\:\\ 0\\.019400415015020243\ \(0\)\
\-\ most\\:\\ 0\\.018309374865225762\ \(0\)\
\-\ t\\-2\\:\\ 0\\.01790465460626076\ \(0\)\
\-\ it\\:\\ 0\\.017826899160399225\ \(0\)\
\-\ strength\\:\\ 0\\.017594607439072953\ \(0\)\
\-\ vegetations\\:\\ 0\\.01723717880010814\ \(0\)\
\-\ tee\\:\\ 0\\.016719444342302547\ \(0\)\
\-\ tonic\\-clonic\\:\\ 0\\.016719444342302547\ \(0\)\
\-\ neurologic\\:\\ 0\\.01655913852346177\ \(0\)\
\-\ miss\\:\\ 0\\.015938766299097875\ \(0\)\
\-\ collosum\\:\\ 0\\.015628948682799678\ \(0\)\
\-\ cryptococcus\\:\\ 0\\.015628948682799678\ \(0\)\
\-\ multicentric\\:\\ 0\\.015628948682799678\ \(0\)\
\-\ ring\\-like\\:\\ 0\\.015355670177796469\ \(0\)\
\-\ has\\:\\ 0\\.01489280715075896\ \(0\)\
\-\ ue\\:\\ 0\\.014688194371643846\ \(0\)\
\-\ 2\\/5\\:\\ 0\\.014688194371643846\ \(0\)\
\-\ biopsy\\:\\ 0\\.01406818209576223\ \(0\)\
\-\ coagulation\\:\\ 0\\.014020718565491221\ \(0\)\
\-\ patient\\:\\ 0\\.013912165931356649\ \(0\)\
\-\ cerebral\\:\\ 0\\.013737570773847196\ \(0\)\
\-\ mri\\:\\ 0\\.013665493189660927\ \(0\)\
\-\ tolerate\\:\\ 0\\.01362199407146185\ \(0\)\
\-\ xrt\\:\\ 0\\.01350298410768563\ \(0\)\
\-\ type\\:\\ 0\\.013367165792793087\ \(0\)\
\-\ eight\\:\\ 0\\.01298524964988004\ \(0\)\
\-\ tumefactive\\:\\ 0\\.012806685749332178\ \(0\)\
\-\ finding\\:\\ 0\\.012779867772800378\ \(0\)\
\-\ toxoplasmosis\\:\\ 0\\.01272230606448096\ \(0\)\
\-\ in\\:\\ 0\\.012710357289613257\ \(0\)\
\-\ le\\:\\ 0\\.012562229796529796\ \(0\)\
\-\ looking\\:\\ 0\\.012562229796529796\ \(0\)\
\-\ isodense\\:\\ 0\\.012562229796529796\ \(0\)\
\-\ area\\:\\ 0\\.01253752317463697\ \(0\)\
\-\ palliative\\:\\ 0\\.012075639237406666\ \(0\)\
\-\ 83\\:\\ 0\\.012075639237406666\ \(0\)\
\-\ identify\\:\\ 0\\.011837462545851949\ \(0\)\
\-\ enough\\:\\ 0\\.011837462545851949\ \(0\)\
\-\ among\\:\\ 0\\.011781551753325126\ \(0\)\
\-\ is\\:\\ 0\\.011741570778335337\ \(0\)\
\-\ panel\\:\\ 0\\.011673616682246488\ \(0\)\
\-\ whole\\:\\ 0\\.011673616682246488\ \(0\)\
\-\ decade\\:\\ 0\\.011673616682246488\ \(0\)\
\-\ centered\\:\\ 0\\.011621475485373964\ \(0\)\
\-\ effects\\:\\ 0\\.01157048034217495\ \(0\)\
\-\ average\\:\\ 0\\.01157048034217495\ \(0\)\
\-\ ultimately\\:\\ 0\\.01157048034217495\ \(0\)\
\-\ 4\\/5\\:\\ 0\\.01147173413702693\ \(0\)\
\-\ periventricular\\:\\ 0\\.011423893563470698\ \(0\)\
\-\ peak\\:\\ 0\\.011286020198109212\ \(0\)\
\-\ men\\:\\ 0\\.011198455632023721\ \(0\)\
\-\ failed\\:\\ 0\\.01107300964299756\ \(0\)\
\-\ deviation\\:\\ 0\\.01107300964299756\ \(0\)\
\-\ hiv\\:\\ 0\\.010992995313366075\ \(0\)\
\-\ sensitive\\:\\ 0\\.010768285740303621\ \(0\)\
\-\ multifocal\\:\\ 0\\.010663597955430142\ \(0\)\
\-\ up\\:\\ 0\\.010662863809996396\ \(0\)\
\-\ survival\\:\\ 0\\.010629726031019115\ \(0\)\
\-\ equal\\:\\ 0\\.010375204181236228\ \(0\)\
\-\ deficit\\:\\ 0\\.010229232428543492\ \(0\)\
\-\ always\\:\\ 0\\.010201108622203943\ \(0\)\
\-\ both\\:\\ 0\\.010126218054227941\ \(0\)\
\-\ adult\\:\\ 0\\.009937166892838148\ \(0\)\
\-\ more\\:\\ 0\\.009917291458525133\ \(0\)\
\-\ alert\\:\\ 0\\.009887799379039344\ \(0\)\
\-\ characterized\\:\\ 0\\.009863504019718474\ \(0\)\
\-\ definitive\\:\\ 0\\.009792108059934822\ \(0\)\
\-\ corpus\\:\\ 0\\.009768789415263124\ \(0\)\
\-\ oriented\\:\\ 0\\.009722843644274308\ \(0\)\
\-\ uncommon\\:\\ 0\\.009700207507510121\ \(0\)\
\-\ right\\-sided\\:\\ 0\\.009677790080800755\ \(0\)\
\-\ appreciated\\:\\ 0\\.00965558717821108\ \(0\)\
\-\ denied\\:\\ 0\\.00965558717821108\ \(0\)\
\-\ women\\:\\ 0\\.009633594732840908\ \(0\)\
\-\ fourth\\:\\ 0\\.009590225514715263\ \(0\)\
\-\ home\\:\\ 0\\.009424427454431865\ \(0\)\
\-\ prognosis\\:\\ 0\\.009404511575797544\ \(0\)\
\-\ hypointense\\:\\ 0\\.009404511575797544\ \(0\)\
\-\ imaging\\:\\ 0\\.009290365774735975\ \(0\)\
\-\ work\\:\\ 0\\.009288478117387656\ \(0\)\
\-\ form\\:\\ 0\\.009269691086685525\ \(0\)\
\-\ \\%\\:\\ 0\\.00924974957469145\ \(0\)\
\-\ like\\:\\ 0\\.009177972203259457\ \(0\)\
\-\ posterior\\:\\ 0\\.009139854054303705\ \(0\)\
\-\ discharged\\:\\ 0\\.009089741587043124\ \(0\)\
\-\ incidence\\:\\ 0\\.009089741587043124\ \(0\)\
\-\ deficits\\:\\ 0\\.009072491056909672\ \(0\)\
\-\ were\\:\\ 0\\.009003648894152767\ \(0\)\
\-\ can\\:\\ 0\\.008994071241155775\ \(0\)\
\-\ distribution\\:\\ 0\\.00892274970856264\ \(0\)\
\-\ poor\\:\\ 0\\.00892274970856264\ \(0\)\
\-\ this\\:\\ 0\\.008920066944910748\ \(0\)\
\-\ seizure\\:\\ 0\\.008766974063927771\ \(0\)\
\-\ life\\:\\ 0\\.008649471203559429\ \(0\)\
\-\ weighted\\:\\ 0\\.008621002311235033\ \(0\)\
\-\ have\\:\\ 0\\.00858671962118372\ \(0\)\
\-\ suspected\\:\\ 0\\.008537633380316092\ \(0\)\
\-\ seizures\\:\\ 0\\.008524025214533267\ \(0\)\
\-\ test\\:\\ 0\\.008470376914252863\ \(0\)\
\-\ but\\:\\ 0\\.008457091884146346\ \(0\)\
\-\ multiple\\:\\ 0\\.008351767997583614\ \(0\)\
\-\ hyperintense\\:\\ 0\\.008231230313000394\ \(0\)\
\-\ specific\\:\\ 0\\.008195625742989581\ \(0\)\
\-\ limits\\:\\ 0\\.008172189325387484\ \(0\)\
\-\ presenting\\:\\ 0\\.008080741602554823\ \(0\)\
\-\ fossa\\:\\ 0\\.008080741602554823\ \(0\)\
\-\ lesion\\:\\ 0\\.008076822394433664\ \(0\)\
\-\ deep\\:\\ 0\\.008025364615532448\ \(0\)\
\-\ extensive\\:\\ 0\\.007928899588048132\ \(0\)\
\-\ 15\\:\\ 0\\.007907996873564685\ \(0\)\
\-\ diagnostic\\:\\ 0\\.007856549408380643\ \(0\)\
\-\ matter\\:\\ 0\\.007806218028772152\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.0076991883959937266\ \(0\)\
\-\ midline\\:\\ 0\\.007670835469462925\ \(0\)\
\-\ used\\:\\ 0\\.007605995723777173\ \(0\)\
\-\ headaches\\:\\ 0\\.007578752526847513\ \(0\)\
\-\ within\\:\\ 0\\.007564414888102467\ \(0\)\
\-\ its\\:\\ 0\\.007481511469734667\ \(0\)\
\-\ confirmed\\:\\ 0\\.007455683533844077\ \(0\)\
\-\ activity\\:\\ 0\\.00743862326863466\ \(0\)\
\-\ weakness\\:\\ 0\\.0073633674084185256\ \(0\)\
\-\ could\\:\\ 0\\.007314519591254181\ \(0\)\
\-\ laboratory\\:\\ 0\\.007306477345369062\ \(0\)\
\-\ abnormalities\\:\\ 0\\.007282516523661755\ \(0\)\
\-\ extremity\\:\\ 0\\.0072509488854812934\ \(0\)\
\-\ presence\\:\\ 0\\.007196718372290322\ \(0\)\
\-\ portion\\:\\ 0\\.007181453938188136\ \(0\)\
\-\ did\\:\\ 0\\.007158743946619313\ \(0\)\
\-\ care\\:\\ 0\\.007151223079045829\ \(0\)\
\-\ required\\:\\ 0\\.007136254087673466\ \(0\)\
\-\ sclerosis\\:\\ 0\\.007121381052033283\ \(0\)\
\-\ involving\\:\\ 0\\.006956861401399753\ \(0\)\
\-\ \\,\\:\\ 0\\.006909073597889005\ \(0\)\
\-\ side\\:\\ 0\\.006868785386923598\ \(0\)\
\-\ presentation\\:\\ 0\\.006829235810884181\ \(0\)\
\-\ headache\\:\\ 0\\.006809710992032014\ \(0\)\
\-\ on\\:\\ 0\\.006718246054435527\ \(0\)\
\-\ less\\:\\ 0\\.0067144779682660844\ \(0\)\
\-\ three\\:\\ 0\\.006683582896396543\ \(0\)\
\-\ white\\:\\ 0\\.0065756478253179065\ \(0\)\
\-\ study\\:\\ 0\\.006523506628445381\ \(0\)\
\-\ a\\:\\ 0\\.006441296085220902\ \(0\)\
\-\ superior\\:\\ 0\\.006331191872515525\ \(0\)\
\-\ often\\:\\ 0\\.006325924706542117\ \(0\)\
\-\ right\\:\\ 0\\.0062758587641096285\ \(0\)\
\-\ found\\:\\ 0\\.006248319291072186\ \(0\)\
\-\ any\\:\\ 0\\.006243236735666575\ \(0\)\
\-\ image\\:\\ 0\\.00619301430695499\ \(0\)\
\-\ be\\:\\ 0\\.0061148803867467705\ \(0\)\
\-\ some\\:\\ 0\\.006020715206187376\ \(0\)\
\-\ no\\:\\ 0\\.005989170422532264\ \(0\)\
\-\ treated\\:\\ 0\\.005934688714811738\ \(0\)\
\-\ negative\\:\\ 0\\.005921392485788571\ \(0\)\
\-\ primary\\:\\ 0\\.00587328135242621\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005817679773682059\ \(0\)\
\-\ the\\:\\ 0\\.005773752029385764\ \(0\)\
\-\ not\\:\\ 0\\.00573001703824564\ \(0\)\
\-\ cystic\\:\\ 0\\.00571840535325234\ \(0\)\
\-\ his\\:\\ 0\\.005714359692916315\ \(0\)\
\-\ two\\:\\ 0\\.005678262732287716\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005666354140114816\ \(0\)\
\-\ t2\\:\\ 0\\.005611574869490376\ \(0\)\
\-\ ct\\:\\ 0\\.0055466526839537955\ \(0\)\
\-\ he\\:\\ 0\\.005531757174090532\ \(0\)\
\-\ however\\:\\ 0\\.005520575535028005\ \(0\)\
\-\ an\\:\\ 0\\.005483363639372296\ \(0\)\
\-\ months\\:\\ 0\\.005415177017842383\ \(0\)\
\-\ are\\:\\ 0\\.005405447204313697\ \(0\)\
\-\ presented\\:\\ 0\\.005404542076618119\ \(0\)\
\-\ one\\:\\ 0\\.005372926643412167\ \(0\)\
\-\ at\\:\\ 0\\.005372450825204793\ \(0\)\
\-\ significant\\:\\ 0\\.005331431904998198\ \(0\)\
\-\ enhancement\\:\\ 0\\.005314359086132334\ \(0\)\
\-\ signal\\:\\ 0\\.0052275506502848694\ \(0\)\
\-\ than\\:\\ 0\\.005195008944125925\ \(0\)\
\-\ for\\:\\ 0\\.005074998714450453\ \(0\)\
\-\ and\\:\\ 0\\.005011851667718379\ \(0\)\
\-\ to\\:\\ 0\\.0049543864088513485\ \(0\)\
\-\ symptoms\\:\\ 0\\.004941200642455079\ \(0\)\
\-\ physical\\:\\ 0\\.004864281367937907\ \(0\)\
\-\ increased\\:\\ 0\\.004850312718792704\ \(0\)\
\-\ upper\\:\\ 0\\.004784409525217444\ \(0\)\
\-\ 1\\:\\ 0\\.004717694589233658\ \(0\)\
\-\ noted\\:\\ 0\\.0046993531054584535\ \(0\)\
\-\ or\\:\\ 0\\.004647437350179617\ \(0\)\
\-\ tumor\\:\\ 0\\.004622348727635292\ \(0\)\
\-\ other\\:\\ 0\\.0045699270271518525\ \(0\)\
\-\ small\\:\\ 0\\.004567460056568721\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004552713064455731\ \(0\)\
\-\ present\\:\\ 0\\.004477978547405292\ \(0\)\
\-\ lower\\:\\ 0\\.004459076727062326\ \(0\)\
\-\ exam\\:\\ 0\\.004355531183177583\ \(0\)\
\-\ \\-\\:\\ 0\\.00424995002020502\ \(0\)\
\-\ after\\:\\ 0\\.004102090957329936\ \(0\)\
\-\ also\\:\\ 0\\.0039086301477265694\ \(0\)\
\-\ which\\:\\ 0\\.003701031524924707\ \(0\)\
\-\ that\\:\\ 0\\.003424549254196806\ \(0\)\
\-\ \\(\\:\\ 0\\.0033520265718972645\ \(0\)\
\-\ \\)\\:\\ 0\\.0033110797777879584\ \(0\)\
\-\ by\\:\\ 0\\.003301324601496229\ \(0\)\
\-\ disease\\:\\ 0\\.0032406903508485014\ \(0\)\
\-\ normal\\:\\ 0\\.003108149546633645\ \(0\)\
\-\ of\\:\\ 0\\.002973414869554229\ \(0\)\
\-\ \\.\\:\\ 0\\.0023885998766195867\ \(0\)\
\-\ with\\:\\ 0\\.0019002998436873043\ \(0\)\
